I performed the initial phase I studies on purine nucleoside analogs in patients with hematologic malignancies and conducted one of the initial phase II studies of fludarabine in patients with CLL. Together with Dr. John C. Byrd, I was among the first to investigate the potential of histone deacetylase inhibitors (depsipeptide) and cyclin-dependent kinase inhibitors (flavopiridol) in CLL, and I oversaw both laboratory and phase I clinical studies of both these agents. My work has been published in such well-respected medical journals as Molecular Cancer Therapeutics, Blood and Journal of Clinical Oncology. I have also been honored with a number of awards, including Best Doctors in America, the Distinguished Alumnus Award from University of Pittsburgh, and more recently, The Ohio State University Distinguished Scholar Award. Additionally, I was named to the Castle Connolly list of “America's Top Doctors” from 2006 to 2019.